Skip Navigation Links
Skip Navigation Links


MATCH: Molecular analysis for therapy choice. Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors or lymphoma.  EAY131 (NCT02465050)  (MBMC Contact: Missy Kuhn 314-996-5868) 

Phase II randomized, double blinded study of the peroxisome proliferator-activated gamma agonist, efatutazone versus plaebo inpatients with previously treated, unresectable, myxoid liposarcoma
Alliance A091202 (NCT02249949) (MBMC Contact: Missy Kuhn 314-996-5868 Temporarily suspended 7/22/16

Randomized phase II study of nivolumab with or without ipilimumb in patients with metastatic or unresectable sarcoma  Alliance 091401 (
NCT02500797) Suspended to preregistration 3/17/16 (MBMC Contact: Missy Kuhn 314-996-5868

Sarcoma Cancer Trials in St. Louis, MO

All contents 2007 Heartland Cancer Research St. Louis, MO. All rights reserved. Privacy Policy